UK markets closed
  • NIKKEI 225

    29,408.17
    -255.33 (-0.86%)
     
  • HANG SENG

    29,095.86
    -356.71 (-1.21%)
     
  • CRUDE OIL

    59.59
    -1.05 (-1.73%)
     
  • GOLD FUTURES

    1,732.80
    +9.80 (+0.57%)
     
  • DOW

    31,391.39
    -144.12 (-0.46%)
     
  • BTC-GBP

    34,072.74
    -687.55 (-1.98%)
     
  • CMC Crypto 200

    950.43
    -36.22 (-3.67%)
     
  • ^IXIC

    13,358.79
    -230.04 (-1.69%)
     
  • ^FTAS

    3,771.68
    +10.23 (+0.27%)
     

Global Kaposi Sarcoma Industry

ReportLinker
·11-min read

Global Kaposi Sarcoma Market to Reach $146. 5 Million by 2027. Amid the COVID-19 crisis, the global market for Kaposi Sarcoma estimated at US$125. 4 Million in the year 2020, is projected to reach a revised size of US$146.

New York, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Kaposi Sarcoma Industry" - https://www.reportlinker.com/p05957194/?utm_source=GNW
5 Million by 2027, growing at a CAGR of 2.2% over the analysis period 2020-2027. HAART, one of the segments analyzed in the report, is projected to record a 2.2% CAGR and reach US$86.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Chemotherapy segment is readjusted to a revised 1.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $36.9 Million, While China is Forecast to Grow at 1.8% CAGR

The Kaposi Sarcoma market in the U.S. is estimated at US$36.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$25.6 Million by the year 2027 trailing a CAGR of 1.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 1.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Immunotherapy Segment to Record 2.7% CAGR

In the global Immunotherapy segment, USA, Canada, Japan, China and Europe will drive the 2.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$16.4 Million in the year 2020 will reach a projected size of US$19.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$16.6 Million by the year 2027.We bring years of research experience to this 9th edition of our report. The 138-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Bristol-Myers Squibb Company

  • Eli Lilly and Company

  • GlaxoSmithKline PLC

  • Johnson & Johnson

  • Merck & Co., Inc.

  • Pfizer, Inc.




Read the full report: https://www.reportlinker.com/p05957194/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Kaposi Sarcoma Competitor Market Share Scenario Worldwide
(in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Kaposi Sarcoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027

Table 2: World Historic Review for Kaposi Sarcoma by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019

Table 3: World 15-Year Perspective for Kaposi Sarcoma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for HAART by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027

Table 5: World Historic Review for HAART by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$ for
Years 2012 through 2019

Table 6: World 15-Year Perspective for HAART by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Chemotherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027

Table 8: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019

Table 9: World 15-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Immunotherapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ for Years 2020 through 2027

Table 11: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ for Years 2012 through 2019

Table 12: World 15-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Kaposi Sarcoma Market Share (in %) by Company: 2019 & 2025
Market Analytics
Table 13: USA Current & Future Analysis for Kaposi Sarcoma by
Segment - HAART, Chemotherapy and Immunotherapy - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027

Table 14: USA Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 15: USA 15-Year Perspective for Kaposi Sarcoma by Segment -
Percentage Breakdown of Value Sales for HAART, Chemotherapy
and Immunotherapy for the Years 2012, 2020 & 2027

CANADA
Table 16: Canada Current & Future Analysis for Kaposi Sarcoma
by Segment - HAART, Chemotherapy and Immunotherapy -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027

Table 17: Canada Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 18: Canada 15-Year Perspective for Kaposi Sarcoma by
Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

JAPAN
Table 19: Japan Current & Future Analysis for Kaposi Sarcoma by
Segment - HAART, Chemotherapy and Immunotherapy - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027

Table 20: Japan Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 21: Japan 15-Year Perspective for Kaposi Sarcoma by
Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

CHINA
Table 22: China Current & Future Analysis for Kaposi Sarcoma by
Segment - HAART, Chemotherapy and Immunotherapy - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027

Table 23: China Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 24: China 15-Year Perspective for Kaposi Sarcoma by
Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

EUROPE
Market Facts & Figures
European Kaposi Sarcoma Market: Competitor Market Share
Scenario (in %) for 2019 & 2025
Market Analytics
Table 25: Europe Current & Future Analysis for Kaposi Sarcoma
by Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
for Years 2020 through 2027

Table 26: Europe Historic Review for Kaposi Sarcoma by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
for Years 2012 through 2019

Table 27: Europe 15-Year Perspective for Kaposi Sarcoma by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2020 & 2027

Table 28: Europe Current & Future Analysis for Kaposi Sarcoma
by Segment - HAART, Chemotherapy and Immunotherapy -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027

Table 29: Europe Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 30: Europe 15-Year Perspective for Kaposi Sarcoma by
Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

FRANCE
Table 31: France Current & Future Analysis for Kaposi Sarcoma
by Segment - HAART, Chemotherapy and Immunotherapy -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027

Table 32: France Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 33: France 15-Year Perspective for Kaposi Sarcoma by
Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

GERMANY
Table 34: Germany Current & Future Analysis for Kaposi Sarcoma
by Segment - HAART, Chemotherapy and Immunotherapy -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027

Table 35: Germany Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 36: Germany 15-Year Perspective for Kaposi Sarcoma by
Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

ITALY
Table 37: Italy Current & Future Analysis for Kaposi Sarcoma by
Segment - HAART, Chemotherapy and Immunotherapy - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027

Table 38: Italy Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 39: Italy 15-Year Perspective for Kaposi Sarcoma by
Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 40: UK Current & Future Analysis for Kaposi Sarcoma by
Segment - HAART, Chemotherapy and Immunotherapy - Independent
Analysis of Annual Sales in US$ for the Years 2020 through 2027

Table 41: UK Historic Review for Kaposi Sarcoma by Segment -
HAART, Chemotherapy and Immunotherapy Markets - Independent
Analysis of Annual Sales in US$ for Years 2012 through 2019

Table 42: UK 15-Year Perspective for Kaposi Sarcoma by Segment -
Percentage Breakdown of Value Sales for HAART, Chemotherapy
and Immunotherapy for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 43: Rest of Europe Current & Future Analysis for Kaposi
Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027

Table 44: Rest of Europe Historic Review for Kaposi Sarcoma by
Segment - HAART, Chemotherapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019

Table 45: Rest of Europe 15-Year Perspective for Kaposi Sarcoma
by Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 46: Asia-Pacific Current & Future Analysis for Kaposi
Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027

Table 47: Asia-Pacific Historic Review for Kaposi Sarcoma by
Segment - HAART, Chemotherapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019

Table 48: Asia-Pacific 15-Year Perspective for Kaposi Sarcoma
by Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

REST OF WORLD
Table 49: Rest of World Current & Future Analysis for Kaposi
Sarcoma by Segment - HAART, Chemotherapy and Immunotherapy -
Independent Analysis of Annual Sales in US$ for the Years 2020
through 2027

Table 50: Rest of World Historic Review for Kaposi Sarcoma by
Segment - HAART, Chemotherapy and Immunotherapy Markets -
Independent Analysis of Annual Sales in US$ for Years 2012
through 2019

Table 51: Rest of World 15-Year Perspective for Kaposi Sarcoma
by Segment - Percentage Breakdown of Value Sales for HAART,
Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 51
Read the full report: https://www.reportlinker.com/p05957194/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001